Immunoassay Market Analysis

Immunoassay Market Analysis

To get key market trends

  Download Free Sample

Based on product, the market size from the reagents & kits segment is poised to expand at 5.1% CAGR from 2024 to 2032. This growth is fueled by their rising usage as integral components of immunoassay procedures for facilitating the detection of specific biomarkers. Researchers and companies are continuously developing new reagents and kits with improved sensitivity and specificity for enhancing the accuracy of immunoassay results. In addition, advancements in technology will continue to drive innovations in reagent and kit development for more efficient and reliable immunoassay methods.
 

In terms of technology, the enzyme-linked immunosorbent assay (ELISA) segment of the immunoassay market is set to reach over USD 23.8 billion by 2032. ELISA methods are continuously being refined for enhanced sensitivity and specificity for allowing the detection of even low concentrations of target molecules. With ongoing efforts, this technology is evolving further to streamline procedures, reduce assay time, and improve automation. Rising advancements to bolster utility in disease diagnosis, drug development, and biomarker discovery will add to the segment growth.
 

In addition, the chemiluminescence immunoassay assay (CLIA) segment is expected to exhibit 6.3% CAGR through 2032. This is due to the growing importance of CLIA in medical diagnostics for their ability to detect antibodies and antigens. Moreover, the continuous advancements for improving sensitivity and reliability for diagnosing various diseases will contribute to the technology demand.
 

On the basis of specimen, the immunoassay market from the blood segment is predicted to witness 5.1% CAGR through 2032. This expansion is due to researchers largely employing blood samples in immunoassays to detect specific biomarkers indicative of various diseases and health conditions. Advancements in immunoassay technology are continuously improving the precision and sensitivity of blood-based assays for enabling earlier and more accurate diagnoses. Blood-based immunoassays will also continue to evolve with ongoing efforts to refine methodologies, expand biomarker panels, and improve point-of-care testing capabilities.
 

Based on application, the infectious diseases segment is projected to reach over USD 18 billion by 2032. Infectious diseases are detected and monitored through immunoassays via a method that relies on antibodies to identify pathogens. Scientists are developing more sensitive immunoassay techniques for enhancing their ability to diagnose infections swiftly and accurately. Rapid advancements for transforming disease surveillance, treatment, and prevention for ensuring timely interventions and improved public health outcomes will favor the segment growth.
 

Meanwhile, the immunoassay market size from the oncology segment is anticipated to record 6.2% CAGR through 2032 due to increasing role in cancer diagnostics for identifying specific biomarkers with high accuracy. Oncology assays are continuously improving through advancements in technology and research. The ongoing evolution is also promising more effective early-stage diagnoses and personalized treatment plans for patients battling cancer.

In terms of end-use, the market value from the hospitals and clinics segment is expected to exceed USD 15.8 billion by 2032. Hospitals and clinics utilize immunoassay technology to diagnose various diseases by employing rapid tests for timely patient care. Moreover, these settings rely on immunoassays with advancements enhancing their accuracy and versatility. Hospitals are also increasingly automated and streamlined, further allowing for quicker turnaround times and broader diagnostic capabilities.

North America immunoassay market size is expected to record 5% CAGR through 2032 driven by the growing demand for innovative diagnostic solutions. The aging population of the region is fueling the demand for healthcare services and diagnostic tools. As a result, companies are continuously expanding their immunoassay product portfolios and investing in R&D activities.
 

Meanwhile, in the U.S. the industry is growing and will reach over USD 17.5 billion by 2032, benefiting from the increasing awareness about the importance of early disease detection. This awareness is driving the demand for advanced diagnostic technologies and encouraging healthcare providers to adopt immunoassays for accurate and timely diagnosis across the country.
 

Asia Pacific immunoassay assay market is set to record 6.2% CAGR over 2024-2032 due to the rising healthcare expenditure. Growing investments are facilitating the increased adoption of advanced diagnostic technologies across healthcare facilities. Surging healthcare spending by governments and private sectors in countries like China, India, and Japan will also add to the regional industry growth.